Want to see ALXO full AI Analyst Report?
ALXO Stock Chart & Stats
$2.03
$0.06(2.71%)
At close: 4:00 PM EDT
$2.03
$0.06(2.71%)
Day’s Range― - ―
52-Week Range$0.60 - $2.66
Previous CloseN/A
Volume153.64K
Average Volume (3M)1.65M
Market Cap
$284.85M
Enterprise Value$153.58
Total Cash (Recent Filing)$138.23M
Total Debt (Recent Filing)$9.71M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 05, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding138,277,000
10 Day Avg. Volume744,812
30 Day Avg. Volume1,645,069
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.72
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside97.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy In CD47‑High PatientsRobust, reproducible responses in CD47‑high cohorts across independent studies indicate a biologically targeted effect. This supports a prospectively selected registrational strategy, concentrates commercial opportunity into a defined biomarker population, and reduces long‑term development risk if assays are validated.
Large Safety Database & Differentiated MOAA sizable safety dataset and an engineered MOA that aims to avoid macrophage activation provide durable clinical development advantages. This lowers combination and regulatory risk, facilitates broad oncology program testing, and supports tolerability expectations important for long‑term adoption.
Extended Funding RunwayAccess to up to $50M of committed capital extends the company's runway to advance mid‑stage and early‑stage programs. This funding durability reduces immediate dilution pressure, enables completion of key enrollment/milestones, and materially supports progression toward registrational readiness.
Bears Say
Pre‑Revenue, Heavy Cash BurnAs a pre‑commercial biotech with sustained negative operating and free cash flow, ALX remains dependent on external financing to fund R&D and trials. Persistent burn constrains strategic optionality, raises dilution risk over time, and can impede ability to complete large registrational studies without additional capital.
Small Sample Sizes & Biomarker RiskCritical efficacy signals rely on very small cohorts, limiting statistical confidence and increasing the chance of regression to the mean. Prospective CD47 assay standardization and larger trials are required; until validated, regulatory pathways and commercial labeling remain uncertain.
Restrictive Secured Loan CovenantsWhile the facility provides capital, its secured nature and restrictive covenants limit strategic flexibility and could accelerate default risk if milestones slip. Over the medium term, these terms may constrain financing options and operational choices critical for executing registrational programs.
ALX Oncology Holdings News
ALXO FAQ
What was Alx Oncology Holdings, Inc.’s price range in the past 12 months?
Alx Oncology Holdings, Inc. lowest stock price was $0.60 and its highest was $2.66 in the past 12 months.
What is Alx Oncology Holdings, Inc.’s market cap?
Alx Oncology Holdings, Inc.’s market cap is $284.85M.
When is Alx Oncology Holdings, Inc.’s upcoming earnings report date?
Alx Oncology Holdings, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 85 days.
How were Alx Oncology Holdings, Inc.’s earnings last quarter?
Alx Oncology Holdings, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.143 by $0.013.
Is Alx Oncology Holdings, Inc. overvalued?
According to Wall Street analysts Alx Oncology Holdings, Inc.’s price is currently Undervalued.
Does Alx Oncology Holdings, Inc. pay dividends?
Alx Oncology Holdings, Inc. does not currently pay dividends.
What is Alx Oncology Holdings, Inc.’s EPS estimate?
Alx Oncology Holdings, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Alx Oncology Holdings, Inc. have?
Alx Oncology Holdings, Inc. has 138,277,000 shares outstanding.
What happened to Alx Oncology Holdings, Inc.’s price movement after its last earnings report?
Alx Oncology Holdings, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.143. Following the earnings report the stock price went up 9.896%.
Which hedge fund is a major shareholder of Alx Oncology Holdings, Inc.?
Currently, no hedge funds are holding shares in ALXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ALX Oncology Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (97.04% Upside)
$4.00 (97.04% Upside)
Blogger Sentiment
Neutral
ALXO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 23.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
275.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.72%
Trailing 12-Months
Company Description
Alx Oncology Holdings, Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
ALXO Company Deck
ALXO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful, reproducible efficacy signals for evorpacept combinations—especially in CD47-high, centrally confirmed HER2-positive patients—with durable responses across independent studies, a large evorpacept safety database, progressing second program (ALX2004), and strengthened corporate resources. However, the clinical findings are preliminary given small exploratory cohorts, CD47 assay/cutoff uncertainty, discordant HER2 testing, and anticipated need for a registrational trial, which introduces execution and regulatory risk. Overall, momentum and positive clinical signals outweigh the limitations, but important validation and prospective biomarker work remain.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$4.00
▲(97.04% Upside)
Technical Analysis
Ownership Overview
9.79% Insiders
3.49% Mutual Funds
0.16% Other Institutional Investors
78.95% Public Companies and
Individual Investors